Covidien plc Releases Clinical Data from Largest Prospective Post-Market Study on Plaque Excision for Treatment of Peripheral Arterial Disease
LAS VEGAS--(BUSINESS WIRE)--Covidien (NYSE:COV), a leading global provider of healthcare products, today released the six-month results of the DEFINITIVE™ LE (Determination of Effectiveness of SilverHawk Peripheral Plaque Excision System for the Treatment of Infrainguinal Vessels/Lower Extremities) study, the largest global post-market peripheral arterial disease (P.A.D.) device study ever undertaken.